Market Cap 166.07M
Revenue (ttm) 10.68M
Net Income (ttm) -27.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -260.49%
Debt to Equity Ratio 0.11
Volume 102,000
Avg Vol 152,506
Day's Range N/A - N/A
Shares Out 30.19M
Stochastic %K 37%
Beta 0.66
Analysts Strong Sell
Price Target $12.31

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices
Sector: Healthcare
Phone: 647 476 1350
Fax: 647 847 3739
Address:
2400 Skymark Avenue, Unit 6, Mississauga, Canada
BioTuesdays
BioTuesdays Oct. 16 at 1:59 PM
$PROF has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and success in treating a broad spectrum of prostate diseases, severities, and aggressions using a unique incision-free, MRI-guided approach https://biotuesdays.com/2025/10/16/profound-congratulates-busch-center-for-500th-tulsa-procedure-achieved/
0 · Reply
healthcareguru
healthcareguru Oct. 10 at 2:01 PM
$PROF Imminent Bankruptcy…or >50% Dilution. Pick your poison bc they are OUT OF CASH NOW. 🐺👎 $XBI $XLV $IWM $IHI
2 · Reply
OnTheBalance
OnTheBalance Oct. 9 at 3:13 PM
$PROF upwards
0 · Reply
Snowlo
Snowlo Oct. 8 at 7:37 PM
$PROF Took a starter position of 500 shares and 5 call options into 2026. This could 100x on the slightest bit of a breakthrough... which seems imminent.
0 · Reply
BioTuesdays
BioTuesdays Oct. 7 at 4:50 PM
$PROF announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of between 84% and 87%. This compares favorably to consensus analyst estimates of $4.7 million in revenue for the quarter https://biotuesdays.com/2025/10/07/profound-sees-record-revenues-in-q3-2025-up-84-87-yoy-with-higher-gross-margin/
0 · Reply
OnTheBalance
OnTheBalance Oct. 7 at 1:29 PM
$PROF accumulators always post BS to assist their accumulation
0 · Reply
healthcareguru
healthcareguru Oct. 7 at 12:41 PM
$PROF you guys release they’re going to miss every single Street estimate, right? Whiff on sales rest of year and guide a mile below for 2026… 👎
1 · Reply
OnTheBalance
OnTheBalance Oct. 6 at 8:23 PM
$PROF Upwards WSJ has 5 analysts on this stock, 4 BUYS, 1 Overweight.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 3:52 PM
$PROF Outstanding article that hits the mark on PROF's current state. So if you want to refresh your PROF insights or learn about PROF from scratch, this is a must read. https://beyondspx.com/quote/PROF/analysis/profound-medical-s-precision-ablation-ignites-mainstream-prostate-care-expansion-nasdaq-prof
2 · Reply
StockScanners
StockScanners Sep. 25 at 1:26 AM
$PROF reached 5.56
0 · Reply
Latest News on PROF
Profound Medical: Smokes Is Everywhere, Initiate At Sell

Aug 18, 2025, 7:01 PM EDT - 2 months ago

Profound Medical: Smokes Is Everywhere, Initiate At Sell


Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 9:24 PM EDT - 2 months ago

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

PRN


Profound Medical Announces Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 2 months ago

Profound Medical Announces Second Quarter 2025 Financial Results


Profound Medical AUA 2025 Investor Event Agenda

Apr 15, 2025, 7:45 AM EDT - 6 months ago

Profound Medical AUA 2025 Investor Event Agenda


BioTuesdays
BioTuesdays Oct. 16 at 1:59 PM
$PROF has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and success in treating a broad spectrum of prostate diseases, severities, and aggressions using a unique incision-free, MRI-guided approach https://biotuesdays.com/2025/10/16/profound-congratulates-busch-center-for-500th-tulsa-procedure-achieved/
0 · Reply
healthcareguru
healthcareguru Oct. 10 at 2:01 PM
$PROF Imminent Bankruptcy…or >50% Dilution. Pick your poison bc they are OUT OF CASH NOW. 🐺👎 $XBI $XLV $IWM $IHI
2 · Reply
OnTheBalance
OnTheBalance Oct. 9 at 3:13 PM
$PROF upwards
0 · Reply
Snowlo
Snowlo Oct. 8 at 7:37 PM
$PROF Took a starter position of 500 shares and 5 call options into 2026. This could 100x on the slightest bit of a breakthrough... which seems imminent.
0 · Reply
BioTuesdays
BioTuesdays Oct. 7 at 4:50 PM
$PROF announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of between 84% and 87%. This compares favorably to consensus analyst estimates of $4.7 million in revenue for the quarter https://biotuesdays.com/2025/10/07/profound-sees-record-revenues-in-q3-2025-up-84-87-yoy-with-higher-gross-margin/
0 · Reply
OnTheBalance
OnTheBalance Oct. 7 at 1:29 PM
$PROF accumulators always post BS to assist their accumulation
0 · Reply
healthcareguru
healthcareguru Oct. 7 at 12:41 PM
$PROF you guys release they’re going to miss every single Street estimate, right? Whiff on sales rest of year and guide a mile below for 2026… 👎
1 · Reply
OnTheBalance
OnTheBalance Oct. 6 at 8:23 PM
$PROF Upwards WSJ has 5 analysts on this stock, 4 BUYS, 1 Overweight.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 3:52 PM
$PROF Outstanding article that hits the mark on PROF's current state. So if you want to refresh your PROF insights or learn about PROF from scratch, this is a must read. https://beyondspx.com/quote/PROF/analysis/profound-medical-s-precision-ablation-ignites-mainstream-prostate-care-expansion-nasdaq-prof
2 · Reply
StockScanners
StockScanners Sep. 25 at 1:26 AM
$PROF reached 5.56
0 · Reply
StockScanners
StockScanners Sep. 24 at 1:37 AM
$PROF keep watch if this holds above 4.85
0 · Reply
FinancialScience
FinancialScience Sep. 23 at 11:57 PM
$PROF https://texasprostate.com/sumbul-shaikh/
0 · Reply
DSWN
DSWN Sep. 23 at 11:03 PM
$PROF On a technical side , five year trend channel resistance at $9.10. Then Fibo at 11.91 Let’s just say, I hope we blow through that 
0 · Reply
QES
QES Sep. 23 at 1:24 PM
$PROF The program is notable for several reasons: It specifically enables Medicare-covered patients to receive the TULSA procedure for both prostate cancer and benign prostatic hyperplasia (BPH) Same-day, minimally invasive treatment with no overnight hospital stay, no procedural blood loss, and a significantly lower risk of side effects like incontinence or erectile dysfunction compared to traditional surgery It demonstrates a novel business model where a private urology practice collaborates with a hospital to deliver this advanced treatment, creating a template that could be replicated nationwide to improve access to state-of-the-art prostate care for Medicare patients.
0 · Reply
RFL2
RFL2 Sep. 22 at 10:31 PM
$PROF anyone have an idea about why the incredibly high volume today? Didn't help the stock but maybe it put in the bottom
2 · Reply
johntarlick
johntarlick Sep. 21 at 1:28 PM
$PROF well i was curious if any of the insiders had bought on the recent dip, as they had done on the similar dip back in the spring. Turns out 3 of the 4 did so again this time, but one did not and that one was, unexpectedly, the CCO. The guy who is under the gun to deliver the goods, right here, right now. And who has strongly asserted he's got dozens of virtually complete sales that will finalize before 2026. One good quarterly report, which will also be the first ever good quarterly report, ought to blow the lid off the stock price and that dip was a golden buying opportunity.
2 · Reply
Bigskies
Bigskies Sep. 20 at 6:53 PM
$PROF This is the time for management to step up and grow the business. I trust that they are getting the equipment installed and promoting its use. Nothing holding them back.
0 · Reply
johntarlick
johntarlick Sep. 12 at 2:02 PM
$PROF hmmm not sure what just happened this week, another lurch. I hesitate to table this, and it's usually just background noise, but the reviews over on glassdoor have recently taken a similar lurch. Sour grapes is one thing, but there is a theme that shows consistently through on almost every single review, and that is, it's great technology. Everyone that has worked on it, has understood it and has liked it.
0 · Reply
RFL2
RFL2 Aug. 24 at 8:15 PM
$PROF the real drawback they don't talk about is a catheter for about a week. Am I wrong?
2 · Reply
SmartMoneyTradez
SmartMoneyTradez Aug. 19 at 2:26 AM
0 · Reply
johntarlick
johntarlick Aug. 17 at 1:10 PM
$PROF I'm inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs 'pipeline' on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can't imagine those numbers aren't to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.
1 · Reply
mlanthoo
mlanthoo Aug. 16 at 3:28 PM
$PROF it seems this management team overpromises and underdelivers on an ongoing basis . time for new direction as current management isn't getting the job done . always an excuse .
0 · Reply